Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDP 023

Next Previous
X
Search
Drug Profile

IDP 023

Alternative Names: IDP-023

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indapta Therapeutics
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HLA antigen modulators; Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
  • Preclinical Multiple sclerosis; Solid tumours

Most Recent Events

  • 06 Aug 2024 Preclinical trials in Multiple sclerosis in USA (Parenteral), prior to August 2024
  • 06 Aug 2024 US FDA approves IND application for IDP 023 in Multiple sclerosis
  • 06 Aug 2024 Indapta Therapeutics in collaboration with Stanford University and the University of California plans a phase I trial for Multiple sclerosis (Combination therapy) in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top